Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans

Skeletal Muscle Physiology Clinical Trial

Official title:

Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans: Myonuclear Addition, Hypertrophy and Myocellular Reprogramming

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05692856
• Other study ID #: CLEN-MEM
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2023
• Est. completion date: August 1, 2025

Study information

• Verified date: January 2023
• Source: University of Copenhagen
• Contact: Morten Hostrup
• Phone: +4535321595
• Email: mhostrup[@]nexs.ku.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the project is investigate muscle memory and underlying mechanisms in humans following resistance training and use of the anabolic substance clenbuterol.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy men and women

• BMI of <26 and normal ECG and blood pressure

Exclusion Criteria:

• Smoking

• Chronic disease,

• Use of prescription medication

• Pain due to current or previous musculoskeletal injury

• Resistance training more than once per week in the 12 months leading up to the intervention

• Current or previous use of prohibited anabolic substances

Related Conditions & MeSH terms

• Skeletal Muscle Physiology

Intervention

Drug:
• Clenbuterol
Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.
• Placebo
Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.

Locations

Country	Name	City	State
Denmark	August Krogh Building	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Morten Hostrup, PhD

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fiber cross-sectional area	Immunohistochemistry to determine fiber cross-sectional area	The change in fiber cross-sectional is assessed at baseline, 8, 24 and 32 weeks
Primary	Myonuclei	Immunohistochemistry to determine number of myonuclei	The change in myonuclei is assessed at baseline, 8, 24 and 32 weeks
Primary	Skeletal muscle proteome	Pathway enrichment analysis of the muscle proteome using mass-spectrometry based proteomics	The change in the muscle proteome is assessed at baseline, 8, 24 and 32 weeks
Secondary	Lean mass	Lean mass assessed by dual X-ray absorptiometry (DXA)	The change in lean mass is assessed at baseline, 8, 24 and 32 weeks
Secondary	Isometric muscle strength	Maximal voluntary isometric contraction of m. quadriceps	The change in maximal voluntary isometric contraction is assessed at baseline, 8, 24 and 32 weeks
Secondary	Dynamic muscle strength	1-repetition maximum	The change in 1-repetition maximum is assessed at baseline, 8, 24 and 32 weeks
Secondary	Sprint performance	Work performed (W) during a sprint on a bicycle ergometer	The change in sprint performance is assessed at baseline, 8, 24 and 32 weeks
Secondary	Satellite cells	Immunohistochemistry to determine number of satellite cells	The change in satellite cells is assessed at baseline, 8, 24 and 32 weeks